UnknownPhase 2NCT04042597

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma

Studying Chordoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University People's Hospital
Principal Investigator
Wei Guo, M.D. and Ph.D.
Musculoskeletal Tumor Center of Peking University People's Hospital
Intervention
Anlotinib Hydrochloride(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2021

Study locations (1)

Collaborators

Peking University Shougang Hospital · Peking University Third Hospital · Peking University First Hospital · Beijing Jishuitan Hospital · Chinese PLA General Hospital · Peking University Cancer Hospital & Institute · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04042597 on ClinicalTrials.gov

Other trials for Chordoma

Additional recruiting or active studies for the same condition.

See all trials for Chordoma →

← Back to all trials